Fig. 3From: Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunctionGenetic alteration analysis of RIPK2 in different cancers. A Genetic alteration frequency and type of RIPK2. B RIPK2 mutation sites in TCGA samples. C Kaplan–Meier survival plots (OS) comparing altered and unaltered group in OV, SARC, and PAADBack to article page